Sales increase of 2.73 million compared to last year period – Transfer of registered office to Austria planned – Continued growth in the new fiscal year 2012/13 expected
Jena, July 31st, 2012 – biolitec AG (ISIN DE0005213409), Jena, listed on the Prime Standard of the Frankfurt Stock Exchange, achieved group sales of 19.36 million Euros in the first two quarters of the 2011/2012 fiscal year. This was 2.73 million Euros higher than that achieved in the same period in the previous fiscal year. The growth in sales is attributable to the constantly rising demand for biolitec treatments; for example, for the benign prostate hyperplasia (LIFE?) and the endoluminal laser treatment for veins (ELVeS?). However, even the new HeLP? (Haemorrhoid Laser Procedure) treatment for the atrophy of haemorrhoidal arteries is a minimally invasive and painless treatment method that has just been successfully launched by biolitec in the market.
Expenses relating to Research & Development for the first half of the 2011/2012 fiscal year for an amount of 1.86 million Euros (approximately 10% of sales) were marginally higher in percentage terms than those in the previous year (1.4 million Euros). Meanwhile, the cost of sales has increased slightly to 5.5 million Euros (compared to 5.0 million Euros in the same period of the previous year).
The gross profit of 12.03 million Euros has remained at the level of the previous year (previous year: 12.05 million Euros) and the Earnings Before Interest and Tax (EBIT) declined to 0.92 million Euros (previous year: 1.2 million Euros).
Significant revenues of biolitec AG were achieved in Europe and North America. The sales in North America of 7.2 million Euros were 8% higher than those in the previous fiscal year. Meanwhile, the sales in Europe reached 7.8 million Euros (previous fiscal year: 6.7 million Euros). Our subsidiaries abroad, particularly in the Middle East and in Asia, delivered sales figures that showed exceptionally high growth rates of 64% (reaching 4.4 million Euros) as compared to the first half of the previous year. Dr. Neuberger, CEO of biolitec AG, states: „Our goal in the medium-term is to increase the share of revenue in these markets to one-third of our sales and thus, to lay the foundation for further growth adapted to the new conditions in the world market. In the process, the continuous enhancement of the installed equipment base will form the basis for dynamic growth in the market for consumable items and in the pharmaceutical business.“
The sales figure for the Meditec segment was 18.35 million Euros in the first half of the fiscal year, while in the pharmaceuticals segment sales jumped by 60% to almost 1.0 million Euros. The earnings per share declined to 0.06 Euro compared to 0.11 Euro in the previous year.
biolitec has decided to publish its results for the first two quarters of 2011/2012 even though the annual statement of accounts for 2010/2011 has not yet been audited (the unaudited sales figure for which was 35.24 million Euros). The tentative sales figures for the 2011/2012 fiscal year for the biolitec group are pegged at 40.27 million Euros. The final figures for 2010/2011 shall be published by biolitec as soon as the auditors have completed the audit of the annual accounts.
In the meantime, biolitec has decided to relocate its registered office to Austria. By moving the registered office to Austria and taking into account the downstream merger in the entry standard associated with it, biolitec AG will not only be able to avail of optimising its tax liabilities such as, for example, the Austrian tax assessment for a group of companies, but it will also find itself closer to the growing markets of the future in Eastern Europe.
An Extraordinary General Meeting of shareholders has been convened for this resolution on 30th August 2012. The invitation and the agenda have appeared in the „Bundesanzeiger“ (Federal Gazette) and have been published on the biolitec website.
For the coming fiscal year 2012/2013, biolitec expects growth to be sustained.
About biolitec®
biolitec® AG worldwide is one of the leading companies in the field of medical laser treatment and the only provider that possesses all the relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PTD). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS® (Endo Laser Vein System) is the laser system most often used worldwide for the treatment of varicose veins, the Evolve? laser has established as gentle treatment in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics and ophtalmology as well as aesthetics also belong to the business field of biolitec®. biolitec® AG is listed in the Prime Standard (ISIN DE0005213409). Further information at www.biolitec.de.
Investor Relations
Jörn Gleisner
Telephone +49 (0) 69 / 959083-20
Telefax +49 (0) 69 / 959083-99
E-Mail: joern.gleisner@biolitec.com
The information does not constitute an offer of or an invitation by or on behalf of biolitec AG or any of its subsidiaries to subscribe for or purchase securities of biolitec AG or any of its subsidiaries.
In particular, the information contained does not constitute an offer of securities for sale or solicitation of an offer to buy securities in the United States of America.
Zum Unternehmen
Die biolitec® AG ist eines der weltweit führenden Unternehmen im Bereich Laseranwendungen und der einzige Anbieter, der über alle relevanten Kernkompetenzen – Photosensitizer, Laser und Lichtwellenleiter – im Bereich der photodynamischen Therapie (PDT) verfügt. Neben der lasergestützten Behandlung von Krebserkrankungen mit dem Medikament Foscan® erforscht und vermarktet die biolitec® AG vor allem minimalinvasive, schonende Laserverfahren. ELVeS® (Endo Laser Vein System) ist das weltweit am häufigsten eingesetzte Lasersystem zur Behandlung der venösen Insuffizienz, der Evolve? Laser hat sich als schonende Behandlungsmethode in der Urologie etabliert. Schonende Laseranwendungen in den Bereichen Proktologie, HNO, Orthopädie und Ophtalmologie sowie Ästhetik gehören ebenfalls zum Geschäftsfeld der biolitec® AG. biolitec® ist im Prime Standard unter der ISIN DE0005213409 notiert. Weitere Informationen unter www.biolitec.de.
Kontakt:
biolitec AG
Jörn Gleisner
Otto-Schott-Straße 15
07745 Jena
+49 (0) 69/959083-20
info@biolitec.de
http://www.biolitec.de
Pressekontakt:
fr financial relations gmbh
Jörn Gleisner
Gutleutstr. 75
60329 Frankfurt
+49 (0) 69 / 959083-20
joern.gleisner@biolitec.com
http://www.biolitec.de